Upcoming Expected Milestones Include OraTech Spin-Off & IPO, Launch of Phase 3 Trial
By M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Planning Spin-off / IPO of JV Company Oramed Pharmaceuticals (NASDAQ:ORMP) formed a JV with Hefei Tianhui Biotech (HTIT), OraTech Pharmaceuticals, which is a strategic initiative to move its assets forward. The JV partners recently made some amendments to their JV agreement to facilitate, among other goals, the planned spin-off and IPO of OraTech following the expected investments of $40.0 million and $7.5 million by HTIT and Oramed, respectively. When / if OraTech lists on Nasdaq, HTIT and ORMP intend to...